Latest news for Scilex Holding (NASDAQ:SCLXW) Stock

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Scilex Holding Co

WIIM

CPTN

Cepton shares are trading higher after the company announced it will be acquired by Koito for $3.17 per share in cash.

William Blair analyst Brian Drab initiates coverage on Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) with a Outperform rating.

News

Initiation

Analyst Ratings

William Blair Initiates Coverage On Modine Manufacturing with Outperform Rating

Truist Securities analyst Keith Hughes maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Buy and raises the price target from $135 to $184.

Price Target

Truist Securities Maintains Buy on Mohawk Industries, Raises Price Target to $184

AMC Entertainment Says This Past Thursday Through Sunday Set Record 2024 Weekend Attendance And Admissions Revenue At Its US Theaters

Full Year 2024&nbsp;Outlook
<ul>
<li>Revenue of&nbsp;$2.5&nbsp;to&nbsp;$2.7 billion</li>
<li>Adjusted EBITDA margin percentage of&nbsp;9.0%&nbsp;to&nbsp;9.6%</li>
<li>Net capital expenditures of&nbsp;$90&nbsp;to&nbsp;$99 million</li>
</ul>

Earnings

Guidance

CTRI

Centuri Initiates 2024 Guidance: Expects Revenue Of $2.5B-$2.7B Vs. $2.877B Est.; Sees Adjusted EBITDA Margin Of 9%-9.6%

Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector
NEW YORK, July 29, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4220850-1&amp;h=1902206349&amp;u=https%3A%2F%2Fwww.genpact.com%2F%3Futm_source%3Dggl%26utm_medium%3Dcpc%26utm_campaign%3D4742272061%26gclid%3DCjwKCAjwgdayBhBQEiwAXhMxtmkQxe9rRGSuwgRGZX_ft9X5PLiFgQ_Uha6gpk0TEnRuF4cb_uwCJhoCeGwQAvD_BwE&amp;a=Genpact">Genpact</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>), a global professional services and solutions firm delivering outcomes that shape the future, has been working&nbsp;with&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4220850-1&amp;h=1429926164&amp;u=https%3A%2F%2Fwww.embecta.com%2Fen-us%2F&amp;a=embecta">embecta</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market.

EMBC

Genpact Has Been Working With embecta's To Support Its Spin-Off Into An Independent Diabetes Care Company

Truist Securities analyst Jordan Levy maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and lowers the price target from $70 to $65.

Truist Securities Maintains Buy on NEXTracker, Lowers Price Target to $65

<a href="https://www.globenewswire.com/Tracker?data=Ru8fqsZhLFqPgdBVQWfW8SQo5ubbmzZknojpTn6lBIv59TZPj4INHZgaXIGNfFZF-e28t3dCgVkurVBfvLYL3w==">Cerence Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>), AI for a world in motion, today announced its collaboration with <a href="https://www.globenewswire.com/Tracker?data=BLdmGdJcBfXzg2p6Op-v10rb7muqVAKoV43V-dIQnW1w7ICaemBNr5W_jTzGeGSe9F_3jL6TJxT6L2SP_29F8HASweTm-M9ZKD2yzBdd-eg=">smart</a>, the new-premium all-electric automobile brand, on the development of AI-powered solutions for smart's next-generation in-car experiences, first available in the <a href="https://www.globenewswire.com/Tracker?data=C3onjwH1m4wAdB4ugZTjXYxlAq6Wu4UWKklCOPG1DBsY_c1xjBkkfND_gHQqAnLMFlVhDxX2Vr7Ul2-lZfTtqiVxvpqovofQH1LUWn6kxCFXa_5cOWiA8ywvQqj6u1EL261GtMFObp65cD2f0VWq4XQlmHPKN3khXJtq-1mZMmaVGbFYUklLrxuG7xto_SvCLrfWo2QcGzDOhpcQ4T2gYw==">Concept #5</a>. smart has always kept a keen focus on emerging technology and remained at the forefront of exploring the best solutions for future urban mobility. In the AI era and with the support of Cerence, smart will create a new generation of future-proof, convenient and sustainable solutions for customers, ensuring an outstanding user experience and setting new industry benchmarks in Europe and other overseas markets outside Mainland China.

Global

CRNC

smart And Cerence Collaborate To Create Next-Gen, Generative AI-Powered In-Car Experience And Setting New Industry Benchmarks In Europe And Other Overseas Markets Outside Mainland China

Lake Street analyst Ryan Meyers initiates coverage on GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) with a Buy rating and announces Price Target of $50.

Lake Street Initiates Coverage On GigaCloud Tech with Buy Rating, Announces Price Target of $50

Truist Securities analyst Jordan Levy maintains Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) with a Buy and raises the price target from $9 to $10.

NOVA

Truist Securities Maintains Buy on Sunnova Energy Intl, Raises Price Target to $10

Asset Entities Inc.&nbsp;("Asset Entities" or "the Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>), a provider of digital marketing and content delivery services across Discord and other social media platforms, and a Ternary Payment Platform company, today announced that the Company received formal notice (the "Notice") from the Nasdaq Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

ASST

Asset Entities Regains Compliance With Nasdaq

Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.22 by 9.09 percent. The company reported quarterly sales of $672.075 million which missed the analyst consensus estimate of $760.424 million by 11.62 percent. This is a 16.59 percent decrease over sales of $805.779 million the same period last year.

Earnings Misses

Centuri Holdings Q2 2024 Adj EPS $0.20 Misses $0.22 Estimate, Sales $672.075M Miss $760.424M Estimate

Truist Securities analyst Michael Roxland maintains Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) with a Hold and lowers the price target from $32 to $31.

Truist Securities Maintains Hold on Weyerhaeuser, Lowers Price Target to $31

Wedbush analyst Richard Anderson maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $22 to $25.

Wedbush Maintains Outperform on Healthpeak Properties, Raises Price Target to $25

- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase with neurodegenerative progression in DLB – &nbsp;
- AscenD-LB Phase 2a results demonstrated neflamapimod treatment led to significant reduction compared to placebo in plasma GFAP levels in patients with DLB and the effects of neflamapimod on plasma GFAP were associated with improvement in CDR-SB -
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), was featured in a poster presentation at the Alzheimer's Association International Conference&#xAE; (AAIC), being held in Philadelphia from July 28-August 1, 2024.

Biotech

General

CRVO

CervoMed Presents On Plasma Biomarker Data, Consistent With Neflamapimod Impacting The Underlying Disease Process In Patients With Dementia With Lewy bodies At AAIC 2024

B of A Securities analyst Derek Hewett maintains Ladder Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LADR#NYSE">LADR</a>) with a Neutral and raises the price target from $11 to $13.

LADR

B of A Securities Maintains Neutral on Ladder Cap, Raises Price Target to $13

Trading Ideas

Centuri Shares Resume Trade

Barclays analyst Carter Gould downgrades Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from Equal-Weight to Underweight and maintains the price target from $41 to $41.

Downgrades

Barclays Downgrades Bristol-Myers Squibb to Underweight, Maintains Price Target to $41

SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>, SVMHW)))) ("SRIVARU" or the "Company"), a provider of premium electric motorcycles, announced today that its state-of-the-art electric motorcycle, the PRANA 2.0, has successfully completed its commercial manufacturing and testing cycle and is now available in the Indian market. The PRANA 2.0 is being manufactured and delivered to its product specifications, ensuring a premium experience for Srivaru's customers. To learn more, please watch the video from SRIVARU's CEO: <a href="https://www.globenewswire.com/Tracker?data=fEmw2JCHNVE-kHKI79aHq7yR0DSgi5w8z33rTZiBIlZf0cnYYNtJCGWy6neUbLbeV1aljVX5-8F_2zd2YT1Sxq8G5nYsZSBqnaRIxtw16RCaQC5n3n1Qs1K51jODy6TFpMWi2WQK-TLHkHAEaYDDdA==">www.svmh.ai/webcasts-presentations/</a>.
Now that this significant milestone has been attained, SRIVARU is poised to commence commercial manufacturing with an automated and fully integrated testing line. This advancement not only showcases SRIVARU'S commitment to innovation but also marks a pivotal moment for the Indian two-wheeled electric vehicle (EV) market.

SVMH

SRIVARU Completes PRANA 2.0 Commercial Manufacturing And Testing Cycle

Will Mentor Anacapa Micro Products And Nara Logics Under Three-Year Contracts, Enhancing Decision Making With Advanced Technologies

Raytheon Awarded Two Mentor-Protégé Agreements From Department Of Navy To Develop Operational AI For Defense

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Scilex Holding

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Scilex Holding

News

Latest news for Scilex Holding (NASDAQ:SCLXW) Stock

People Also Watch